



Albireo  
10 Post Office Square  
Suite 502 South  
Boston, MA 02109  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ALBO**

Last Trade:	24.74
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	-0.66 <span style="color: red;">▼</span> (-2.598%)
Day Range	24.20 - 25.02
52-Week Range	10.89 - 37.69
Volume	13,108

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Albireo Pharma is a clinical-stage company focused through its operating subsidiary on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 30, 2017*  
[Albireo Announces Closing of \\$51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares](#)
- May 24, 2017*  
[Albireo Prices \\$45.1 Million Public Offering of Common Stock](#)
- May 23, 2017*  
[Albireo Announces Proposed Public Offering of Common Stock](#)
- May 18, 2017*  
[Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC](#)
- May 16, 2017*  
[Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 27, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 11, 2017*  
[Quarterly Report \(10-Q\)](#)